Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

Semaglutide patent: Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.

20 Mar 2026, 06:35 · www.ndtv.com

Show
Quick Read
Summary is AI-generated, newsroom-reviewed

Semaglutide, a GLP-1 drug, aids diabetes and obesity by controlling glucose and appetite
Patent expiry from March 20, 2026, will allow generic, more affordable versions of semaglutide
Affordable semaglutide may improve access, reducing complications and hospitalisations globally

Did our AI summary help?
Let us know.
Switch To Beeps Mode

The global conversation around obesity and type 2 diabetes management has shifted dramatically in recent years, largely due to the rise of GLP-1 receptor compounds. Among them, semaglutide has emerged as one of the most effective modern therapies, transforming how clinicians approach both blood sugar control and weight management. However, high costs and limited availability have meant that many patients, especially in price-sensitive countries, could not easily access this treatment.

That situation will now change as patent protections begin to expire in several markets starting March 20, 2026, opening the door to more affordable generic versions.

Understanding Semaglutide and How It Works

Semaglutide belongs to a class of medicines known as GLP-1 receptor compounds. These drugs mimic the action of a naturally occurring hormone called glucagon-like peptide-1, which is released in the gut after eating.

This hormone plays multiple roles in the body:

It stimulates insulin release when blood sugar levels rise
It reduces excess glucose production in the liver
It slows the rate at which the stomach empties
It acts on appetite centres in the brain to promote a feeling of fullness

Together, these effects help patients achieve better long-term glucose control while also reducing calorie intake. Unlike many older therapies, semaglutide addresses both diabetes and obesity simultaneously, the two conditions that frequently occur together and significantly raise cardiovascular risk.

What Patent Expiry Really Means

When a pharmaceutical patent expires, other manufacturers are legally allowed to produce medicines containing the same active ingredient. These are known as generic drugs. However, to say this with certainty, generic molecules need to undergo bioequivalence trials with the innovator/original molecule to see if one unit of the generic molecule is equivalent to one unit of the original molecule.

Generics are essentially identical to their branded counterparts in terms of dosage, safety, effectiveness and quality standards. Regulatory authorities require them to undergo strict evaluation before approval, ensuring patients receive the same therapeutic benefit at a lower cost.

Patent expiry therefore does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.

Why Greater Access Matters for Patients

Obesity and type 2 diabetes are rising rapidly across the world, driven by sedentary lifestyles, dietary changes and genetic predisposition. Both conditions increase the likelihood of heart disease, kidney failure and stroke, placing a heavy burden on families and healthcare systems.

For many patients, lifestyle modification alone is not sufficient. While balanced diets, exercise and behavioural therapy remain essential, some individuals require medical support to regulate appetite, improve metabolism and reduce cardiometabolic risk.

Until recently, semaglutide treatment was financially out of reach for a large section of patients. Monthly therapy costs often consumed a significant share of household income, especially where health insurance coverage is limited.

Lower-priced generics could allow:

Earlier medical intervention
Better long-term disease control
Reduced risk of complications
Fewer hospitalisations
Improved quality of life

In public health terms, broader access may help shift treatment from crisis management to preventive care.

Special Considerations for Asian Populations

Emerging research suggests that many Asian populations develop metabolic complications at lower body mass index (BMI) levels than Western populations. A phenotype often described as "thin-fat" - where individuals appear lean but carry high visceral fat. This increases vulnerability to diabetes and heart disease even when BMI falls within traditional "normal" ranges.

Because semaglutide has shown particular effectiveness in reducing visceral fat, it could play an important preventive role in such populations. However, treatment eligibility criteria in many countries still rely heavily on BMI thresholds derived from Western data.

Public health authorities may therefore need to adapt guidelines to ensure that high-risk individuals are not excluded from potentially beneficial therapy.

Affordability vs Responsible Use

While lower prices are welcome, wider access also brings responsibility. Semaglutide is a powerful prescription medicine, not a cosmetic weight-loss shortcut.

Improper or unsupervised use can lead to:

Gastrointestinal side effects
Nutritional deficiencies
Muscle loss from rapid weight reduction
Weight regain after stopping treatment

Medical supervision ensures gradual dose adjustments, dietary planning, strength training and monitoring for adverse effects. The medicine works best when combined with sustainable lifestyle changes rather than used as a quick fix.

The Bigger Picture

Patent expiry represents more than a legal milestone. It signals a potential public-health turning point. As prices fall and availability improves, semaglutide-based treatment may become accessible to millions who previously had limited options.

However, true accessibility depends not only on cost, but also on appropriate prescribing guidelines, patient awareness, regulatory oversight and healthcare infrastructure.

If these elements align, the post-patent era could mark an important step forward in tackling two of the most pressing metabolic health challenges of our time.

(By Dr. Hari Kishan Boorugu, Consultant Physician & Diabetologist, Yashoda Hospitals, Hyderabad)

Disclaimer: The opinions expressed within this article are the personal opinions of the author. NDTV is not responsible for the accuracy, completeness, suitability, or validity of any information on this article. All information is provided on an as-is basis. The information, facts or opinions appearing in the article do not reflect the views of NDTV and NDTV does not assume any responsibility or liability for the same.

Show full article

Track Latest News Live on NDTV.com and get news updates from India and around the world